ProKidney Corp

NAS:PROK (USA)   Ordinary Shares - Class A
$ 1.70 -0.1 (-5.56%) 11:09 PM EST
At Loss
Market Cap:
$ 230.34M
Enterprise V:
$ 1.25B
Volume:
444.69K
Avg Vol (2M):
469.29K
Trade In:
Volume:
444.69K
At Loss
Avg Vol (2M):
469.29K

Business Description

ProKidney Corp
NAICS : 541714 SIC : 8731
ISIN : KYG7S53R1049

Share Class Description:

PROK: Ordinary Shares - Class A
Description
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
Name Current Vs Industry Vs History
Cash-To-Debt 63.18
Equity-to-Asset -2.06
Debt-to-Equity -0.01
Debt-to-EBITDA -0.05
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -144
3-Year EPS without NRI Growth Rate -58.6
3-Year FCF Growth Rate -130.7

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 46.23
9-Day RSI 45.42
14-Day RSI 46.02
6-1 Month Momentum % -23.55
12-1 Month Momentum % -12.74

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.09
Quick Ratio 17.09
Cash Ratio 16.16

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 31.5
Shareholder Yield % -1.47
Name Current Vs Industry Vs History
ROA % -10.21
ROIC % -290.55
ROC (Joel Greenblatt) % -292.24
ROCE % -32.05

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -9.21
EV-to-Forward-EBIT -0.02
EV-to-EBITDA -9.56
EV-to-Forward-EBITDA -0.02
EV-to-FCF -9.41
Earnings Yield (Greenblatt) % -10.86
FCF Yield % -57.8

Financials (Next Earnings Date:2025-03-21 Est.)

PROK's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:PROK

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

ProKidney Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.55
Beta 0
Volatility % 97.03
14-Day RSI 46.02
14-Day ATR ($) 0.188856
20-Day SMA ($) 1.85
12-1 Month Momentum % -12.74
52-Week Range ($) 1.18 - 4.44
Shares Outstanding (Mil) 127.97

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 0
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

ProKidney Corp Filings

Filing Date Document Date Form
No Filing Data

ProKidney Corp Stock Events

Financials Calendars
Event Date Price($)
No Event Data

ProKidney Corp Frequently Asked Questions

What is ProKidney Corp(PROK)'s stock price today?
The current price of PROK is $1.70. The 52 week high of PROK is $4.44 and 52 week low is $1.18.
When is next earnings date of ProKidney Corp(PROK)?
The next earnings date of ProKidney Corp(PROK) is 2025-03-21 Est..
Does ProKidney Corp(PROK) pay dividends? If so, how much?
ProKidney Corp(PROK) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1